Selank dosage: what published studies administered, and to whom

The short version

This page describes Selank dosage only in the way published studies recorded it — what was given, to which species, by which route. It is not a how-to, and it contains no instruction for any person. In animal work, researchers commonly used roughly 100 to 300 micrograms per kilogram of body weight, given into the nose or by injection. The human studies that exist used a 0.15% liquid given as nasal drops over courses of a few weeks, under medical supervision in diagnosed patients in Russia. Two honest points shape everything below: the peptide itself clears from the body fast (a matter of minutes), and rigorous human dosing data outside those Russian trials simply do not exist. Selank is not FDA-approved, and nothing here should be read as a recommended amount to take.

Selank dosage in published research

In the published record, Selank dosage is reported in research terms rather than as a consumer protocol. Animal studies frequently used 100–300 µg/kg, administered intranasally or systemically — for example, the rat GABA-pathway gene-expression study used 300 µg/kg ^[4]. These are doses administered to animals by investigators, expressed per kilogram of body weight; they do not translate into a human amount, and this site does not perform that translation.

Human exposure in the literature is confined to the Russian clinical formulation: a 0.15% aqueous intranasal solution applied as nasal drops, given over multi-week courses as an alternative or adjunct to benzodiazepine therapy in diagnosed patients under supervision ^[6][16].

Selank nasal spray and the intranasal route

The intranasal route is the primary clinical route for Selank in Russia, and the Selank nasal spray (more precisely, nasal drops of the 0.15% solution) is the form most human data describe ^[6]. The route has mechanistic support: a comparison of intranasal versus intraperitoneal administration in mice found that Selank produced comparable central pharmacological effects intranasally, supporting nasal delivery as a viable route to the brain ^[12]. Other routes studied in rodents include intraperitoneal, subcutaneous, and intravenous administration. As noted on Selank effects, nasal irritation is a commonly reported tolerability complaint with intranasal use, attributed to the carrier rather than the peptide.

Selank peptide protocol in study design

A Selank peptide protocol, in the research sense, refers to how a study structured administration — dose, route, frequency, and duration — not to a personal regimen. The human investigations used multi-week intranasal courses (on the order of two to three weeks) ^[6][16]; animal protocols ranged from single doses (as in the gene-expression time-course at one and three hours ^[4]) to repeated administration in stress and memory models ^[7][13]. Because the peptide is short-lived, study designs often relied on the intranasal route and on the activity of metabolites rather than on sustained parent-compound levels. These are descriptions of study methodology, offered for understanding the literature, and are not a template for use.

Selank side effects in context

Within the published clinical work, the notable Selank side effects signal is its near-absence relative to comparators: the Russian GAD studies reported an anxiolytic effect without the sedation, cognitive impairment, or dependence seen with benzodiazepines ^[6]. That favorable short-term tolerability is a genuine reported finding — but, as detailed on Selank effects, it comes from short, single-region trials and cannot substitute for long-term human safety data ^[16][17]. Community-reported tolerability (nasal irritation, occasional headache, over-calm with frequent redosing) is anecdotal and kept separate from this cited clinical record.

Stability, storage, and formulation notes

The Pro-Gly-Pro extension that defines Selank slows enzymatic degradation relative to native tuftsin, which is the molecule's core stabilization rationale ^[2]. For research handling, the peptide is typically supplied lyophilized (freeze-dried); reconstituted solutions are kept refrigerated. The Russian clinical product is the standardized 0.15% intranasal solution ^[6]. None of this is a preparation instruction for human use — it is a description of how the material is characterized and handled in a research setting, where, as noted throughout this site, purity and identity vary by supplier and are not independently guaranteed ^[6].